A practical reference on SR9009: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-25 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
==== Agrochemicals ==== Agrochemical companies are the second largest users of fine chemicals. Most products have a "pharmaceutical heritage". As a consequence of an intensive M&A activity (Mergers and Acquisitions) over the past 10–20 years, the industry now is more consolidated than the pharmaceutical industry. The top 10 companies, led by Syngenta, Switzerland; Bayer Cropsciences, Germany: Monsanto, USA; BASF Crop Protection, Germany, and Dow Agrosciences, USA have a share of almost 95% of the total 2,000,000 tons / $48.5 billion pesticide output in 2010. Since the 1990s, the R&D effort has been focused mainly on gene modified (GM) seeds. At both Monsanto and DuPont's seed subsidiary, Pioneer Hi-Bred, the GM seed businesses already account for more than 50% of total sales. 100 new LMW agrochemicals were launched between 2000–2009. However, only 8 products achieved sales in excess of $100 million per year. Generics play a bigger role in the agro than in the pharma industry. They represent some 70% of the global market. China National Chemical Corp is the world's largest supplier of generic farm chemicals. Mahkteshim Agan, Israel, and Cheminova, Denmark, rank second and third. Apart from these multibillion-dollar companies, there are hundreds of smaller firms with sales of less than $50 million per year, mainly in India and China. The incidence of the cost of the active ingredient is about 33%, much higher than in drugs.
=== PTQ implant === This is a silicone biomaterial, marketed as "PTQ" or "Bioplastique". It is polydimethylsiloxane elastomer particles suspended in a biocompatible carrier hydrogel of poly-N-vinyl-pyrrolidone (povidone). Significantly more publications exist which investigate this material compared to the other materials, and it has been the most widely used bulking material used for FI. Publications used inter-sphincteric or within IAS injection sites via the trans-sphincteric route. The particles are in the range 100–450 μm with smaller particles in the gel. Therefore there is a possibility of migration and granuloma formation. There are also concerns about a link between autoimmune diseases and silicone. The bulking agent is very viscous which makes it difficult to inject. After injection there is irregular collagen deposition around and inside the implant.
=== Genetics === Alport syndrome is caused by mutations in COL4A3, COL4A4, and COL4A5, three of six human genes involved in basement membrane (type IV) collagen biosynthesis. Mutations in any of these genes prevent the proper production or assembly of the specialised type IV collagen '345' network which is an important structural component of basement membranes in the kidney, inner ear, and eye. It is also found in other locations, including the alveoli of the lungs. Basement membranes are thin, sheet-like structures that separate and support cells in many tissues. Type IV collagen '112' type is found in both vertebrates and invertebrates and is the major isoform in most human basement membranes. When mutations prevent the formation of 345 type IV collagen network in the glomerulus, the 112 network, which is formed in fetal development but usually replaced by 345, persists into adult life.
In 2007, she appeared opposite Milla Jovovich in Resident Evil: Extinction, portraying Claire Redfield, who in the film, is the leader of a convoy of zombie apocalypse survivors going to Alaska in search of a safe haven. Her role sent her to Mexicali, Mexico for filming from May to late July, and required her hair to be dyed a light red. Speaking about her character Claire, Larter said, "She became the leader of this convoy. She's incredibly strong, patient. I think she serves a role for everyone within this convoy, let it be a mother to someone, a buddy, a best friend." Despite negative reviews, the film made $147 million worldwide. Also in the same year, she appeared with Hayes MacArthur in the comedy Homo Erectus and appeared as Evelyn Garland in the biographical drama Crazy, based on guitarist Hank Garland. Larter starred opposite Beyoncé and Idris Elba from London, in the Screen Gems-produced thriller Obsessed (2009). The film follows an office executive Derek Charles (Elba) whose marriage to Knowles' character Sharon is threatened by the aggressive interests of a co-worker Lisa Sheridan, portrayed by Larter. In an interview with Glam, Larter said that she "was excited to get the chance to play a femme fatale. I love playing women that are dark and vulnerable and sort of filled with a little bit of crazy emotion." While the film was released to mixed reviews, Larter was critically praised for her performance.
Sources: en.wikipedia.org
An artificial neural network is based on a collection of nodes also known as artificial neurons, which loosely model the neurons in a biological brain. It is trained to recognise patterns; once trained, it can recognise those patterns in fresh data. There is an input, at least one hidden layer of nodes and an output. Each node applies a function and once the weight crosses its specified threshold, the data is transmitted to the next layer. A network is typically called a deep neural network if it has at least 2 hidden layers. Learning algorithms for neural networks use local search to choose the weights that will get the right output for each input during training. The most common training technique is the backpropagation algorithm. Neural networks learn to model complex relationships between inputs and outputs and find patterns in data. In theory, a neural network can learn any function. In feedforward neural networks the signal passes in only one direction. The term perceptron typically refers to a single-layer neural network. In contrast, deep learning uses many layers. Recurrent neural networks (RNNs) feed the output signal back into the input, which allows short-term memories of previous input events. Long short-term memory networks (LSTMs) are recurrent neural networks that better preserve longterm dependencies and are less sensitive to the vanishing gradient problem. Convolutional neural networks (CNNs) use layers of kernels to more efficiently process local patterns.
A NATO spokesperson said, "discussions among NATO allies on the framework [Trump] referenced will focus on ensuring Arctic security through the collective efforts of allies, especially the seven Arctic allies". Greenland prime minister Jens-Frederik Nielsen emphasised that "nobody else than Greenland and the Kingdom of Denmark have the mandate to make deals or agreements about Greenland and the Kingdom of Denmark". Trump's comments in Davos were described as a great climbdown. Reuters reported that his reversal of policy followed pressure by his own aides opposing an invasion of Greenland. Former American NATO ambassador R. Nicholas Burns said Trump had clearly backed down in the face of tough military, economic, and political resistance from the Europeans that the Trump administration had not calculated. Trump's behaviour during 2025 and 2026 was described as having damaged the United States standing in the world and how allies see the nation in the long term, while resulting in no other outcome than maintaining Greenland's status quo. CNN reported that no actual document exists yet and that the information available indicates that the supposed deal "sounds a lot like what the United States already had", and described the affair as "one of the most erratic episodes involving a modern president on the world stage". Greenlandic politician Tillie Martinussen said: "We can never really trust America again." Trump's reversal was widely referred to as a TACO moment. The New York Times argued that it showed the "limits of his coercive powers".
== Treatment == There are two different main mechanism of treatment for toxification with AzM. One possibility is to treat the patient before exposure to AzM and the other one is to treat the patient after poisoning. Competitive antagonists of AChE can be used for pre-treatment. They can reduce mortality, which is caused by exposure to AzM. Organophosphorus AChE inhibitors can bind temporally to the catalytic site of the enzyme. Because of this binding, AzM cannot phosphorylate the enzyme anymore and the enzyme is shorter inhibited. The mechanism for treatment after exposure is to block the muscarinic receptor activation. Anticonvulsants are used to control the seizures and oximes are used to reactivate the inhibited AChE. Oximes remove the phosphoryl group bound to the active site of the AChE by binding to it. There are a few oximes that are the most efficacious by AzM poisoning, namely oxime K-27 and physostigmine. These two treatments are also used together, some patients are namely treated with atropine (a competitive antagonist of AChE) and reactivating oximes. When patients are resistant to atropine, the patients can be treated with low doses of anisodamine, a cholinergic and alpha-1 adrenergic antagonist, to achieve a shorter recovery time. Treatment with a combination of different alkaloids or synergistically with atropine is safer than using high antroponine concentrations, which can be toxic. Another possibility is to use membrane bioreactor technology. When this technology is used, no other chemical compounds need to be added.
Sources: en.wikipedia.org
=== Conversion to imines === Imine formation is an important reaction. Primary amines react with ketones and aldehydes to form imines. In the case of formaldehyde (R' = H), these products typically exist as cyclic trimers:
After being forced to delay for several weeks at Bloemfontein by a shortage of supplies, an outbreak of typhoid at Paardeberg, and poor medical care, Roberts finally resumed his advance. He was forced to halt again at Kroonstad for 10 days, due once again to the collapse of his medical and supply systems, but captured Johannesburg on 31 May and the capital of the Transvaal, Pretoria, on 5 June. Before the war, the Boers had constructed forts south of Pretoria, but the artillery had been removed from the forts for use in the field, and in the event they abandoned Pretoria without a fight. Having won the principal cities, Roberts declared the war over on 3 September 1900; and the South African Republic was formally annexed.
Minerva was featured as a Mod of the Week on Planet Half-Life. Amped News rated it 4.5/5. An interview with Adam Foster in the February 2006 edition of Computer Gaming World. ModDB gave Minerva a Mod Of The Year 2006 Award (5th place). RockPaperShotgun posted an interview with Adam Foster in October 2007. RockPaperShotgun featured Minerva: Metastasis on the eight day of its 2007 Advent Game-O-Calendar series.
=== Exoenzymes === Exoenzymes are enzymes secreted by microorganisms, such as bacteria and fungi, to function outside their cells. These enzymes are crucial for breaking down large molecules in the environment into smaller ones that the microorganisms can absorb (transport into their cells) and use for growth and energy. Several studies have demonstrated that the activity of extracellular enzymes in aquatic microbial ecology is of algal origin. These exoenzymes released from microalgae include alkaline phosphatases, chitinases, β-d-glucosidases, proteases etc. and can influence the growth of microorganisms, chemical signaling, and biogeochemical cycling in ecosystems. The study of these exoenzymes may help to optimize the nutrient supplement strategy in aquaculture. Nevertheless, only a few of the enzymes were isolated and purified. Selected prominent enzyme classes are highlighted in the cited literature.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.